# Hemorrhage Risk Prescribed Arixtra

> **NCT01064362** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 13442 (actual)

## Conditions studied

- Thrombosis, Venous

## Interventions

- **DRUG:** Fondaparinux sodium
- **DRUG:** Low molecular weight heparin (LMWH)

## Key facts

- **NCT ID:** NCT01064362
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 13442 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064362, "Hemorrhage Risk Prescribed Arixtra". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01064362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*